Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease. — We retrospectively reviewed 20 consecutive patients with Alzheimer's disease who switched from lecanemab to donanemab. No new amyloid-related imaging abnormalities (ARIA) or significant adverse events were...

Evidence span

Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease. — We retrospectively reviewed 20 consecutive patients with Alzheimer's disease who switched from lecanemab to donanemab. No new amyloid-related imaging abnormalities (ARIA) or significant adverse events were...

From Arai H et al. 2025, Journal of Alzheimer's disease : JAD

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Retrospective Studies; Aged; Aged, 80 and over — Journal of Alzheimer's disease : JAD 2025

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required